BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2022 12:06:55 PM | Browse: 220 | Download: 356
 |
Received |
|
2020-11-27 06:27 |
|
Peer-Review Started |
|
2020-11-30 18:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-09-28 03:32 |
|
Revised |
|
2021-10-12 15:52 |
|
Second Decision |
|
2022-02-24 06:14 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-02-27 20:06 |
|
Articles in Press |
|
2022-02-27 20:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-03-14 06:18 |
|
Publish the Manuscript Online |
|
2022-04-08 12:06 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fang Yuan, Nan Liu, Ming-Zhen Yang, Xiao-Tian Zhang, Hong Luo and Hong Zhou |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Major Project of Chongqing Health Committee |
cstc2016 shmszx130033031 |
| the Natural Science Foundation of Chongqing |
No.cstc2018jcyjAX0781 |
| the National Natural Science Foundation of China |
81302316 |
| Chongqing technological innovation and application development - Major theme projects |
cstc2019jscx-fxydx0008 |
|
| Corresponding Author |
Hong Zhou, MD, Professor, Surgical Oncologist, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, 181 Hanyu Road, Shapingba, Chongqing, China, Chongqing 400044, China. zhouhongcqch@126.com |
| Key Words |
mCRPC; Olaparib; Circulating tumor DNA; Partner and localizer of BRCA2; Resistance mechanism; Reverse missense mutations |
| Core Tip |
This case report describes the poly (ADP-ribose) polymerase inhibitor olaparib treatment response in a patient with metastatic castration-resistant prostate cancer (mCRPC). The patient’s course of response to ‘final choice’ therapy (olaparib-abiraterone-prednisone combination treatment), consisting of serum total prostate-specific antigen (TPSA) level reduction and symptom remission for 4 months followed by TPSA rise, prompted comprehensive genomic profiling of circulating tumor (ct) DNA, which revealed reverse missense mutations in the partner and localizer of BRCA2 gene. Timely multigene testing by ctDNA, especially in mCRPC, can determine the most appropriate and accurate therapeutic approach and explore the resistance mechanism. |
| Publish Date |
2022-04-08 12:06 |
| Citation |
Yuan F, Liu N, Yang MZ, Zhang XT, Luo H, Zhou H. Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. World J Clin Cases 2022; 10(11): 3461-3471 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i11/3461.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i11.3461 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
